Fatigue is one of the most common symptoms of Lyme disease, yet it is frequently overlooked, underestimated, or attributed to other causes. Research shows fatigue is present across every stage of Lyme disease, from early infection to chronic neurologic involvement, and may be one of the most important signals that infection has not resolved.
Fatigue in Early Lyme Disease
Researchers at New York Medical College found that 51% of patients with erythema migrans had measurable fatigue, and 19.6% had severe fatigue based on the Fatigue Severity Scale. They attributed the fatigue to proinflammatory cytokines and the acute sickness response, the body’s immune reaction to active infection.
Fatigue as a Predictor of Persistent Illness
Fatigue is not just an early symptom. Individuals with an elevated T-cell chemokine CCL19 after a 3-week course of doxycycline had a 12-fold higher risk of developing Post-Treatment Lyme Disease Syndrome (PTLDS). PTLDS has been defined as persistent fatigue, musculoskeletal pain, and cognitive complaints with functional impact.
Fatigue has also been documented in chronic neurologic Lyme disease, Lyme encephalopathy, and post-Lyme disease, making it one of the most consistent findings across all stages of illness.
Clinical Trials Show Fatigue Can Improve with Treatment
Severe fatigue has been successfully treated in randomized clinical trials of patients with persistent illness.
In a study of post-treatment Lyme disease, 64% of patients who received 1 month of IV ceftriaxone improved on the Fatigue Severity Scale at 6 months, compared to 18.5% who received placebo (p less than 0.001).
In a study of Lyme encephalopathy, 66.7% of patients who received 10 weeks of IV ceftriaxone improved at 6 months, compared to 25% who received placebo (p = 0.05).
These findings demonstrate that Lyme disease fatigue is not simply subjective. It is measurable, treatable, and responsive to antibiotics in a significant percentage of patients.
Why Fatigue Is Overlooked in Lyme Disease
Fatigue is also a feature of chronic fatigue syndrome, fibromyalgia, multiple sclerosis, and many other conditions. This makes it easy to attribute to another diagnosis or to dismiss entirely.
It is particularly important to identify individuals who may have a persistent tick-borne infection and could benefit from treatment. When fatigue is the primary complaint and there is any history of tick exposure, Lyme disease and coinfections should remain on the differential.
This pattern of dismissal reflects broader challenges in Lyme disease care, where treatable symptoms are attributed to stress, aging, or depression without adequate evaluation.
Measuring Fatigue in Clinical Practice
Fatigue can be assessed using the Visual Analogue Scale (VAS), the 11-item Fatigue Severity Scale (FSS-11) over a 14-day period, or the 36-item Short-Form General Health Survey over a 28-day period. All three measures are positively correlated.
The VAS is already used in clinical practice to assess pain. It has been used for over 25 years to assess fatigue in patients with suspected Lyme disease, providing an objective measure for a symptom that is too often treated as subjective.
Clinical Takeaways
Fatigue affects 51% of early Lyme disease patients and predicts persistent illness. Randomized trials show 64% improvement with IV ceftriaxone. Fatigue is often overlooked despite being measurable, treatable, and responsive to antibiotics.
Frequently Asked Questions
How common is fatigue in early Lyme disease?
51% of patients with erythema migrans had measurable fatigue, and nearly 20% had severe fatigue at diagnosis.
Why is fatigue from Lyme disease often overlooked?
Fatigue is common across many conditions, making it easy to attribute to stress, depression, or another diagnosis without evaluating for Lyme disease.
Does Lyme disease fatigue respond to antibiotic treatment?
Yes. Randomized trials showed 64 to 67% of patients with persistent Lyme disease improved on fatigue measures after IV ceftriaxone.
References
- Wormser GP, Sudhindra P, Lopez E, et al. Fatigue in patients with erythema migrans. Diagn Microbiol Infect Dis. 2016;84(2):157-159.
- Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990;323(21):1438-1444.
- Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992-1003.
- Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60(12):1923-1930.
- Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a Chemokine Risk Factor for Post-Treatment Lyme Disease Syndrome. Clin Vaccine Immunol. 2016;23(9):757-766.
